Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | GSK3B (Glycogen Synthase Kinase 3 Beta) |
|---|
| Gene | GSK3B |
|---|
| UniProt ID | P49841 |
|---|
| PDB ID | 1J1B, 1I09, 3L1L |
|---|
| Molecular Weight | 46.7 kDa |
|---|
| Subcellular Localization | Cytoplasm, Nucleus, Mitochondria, Synapse |
|---|
| Protein Family | Serine/Threonine Protein Kinase Family |
|---|
GSK3B is a serine/threonine-protein kinase that plays a central role in neuronal signaling, synaptic plasticity, and the pathogenesis of neurodegenerative diseases. It is one of the most important tau kinases and is implicated in Alzheimer's disease through tau hyperphosphorylation and amyloid-beta signaling.
GSK3B is a 420-amino acid protein with:
- N-terminal kinase domain (residues 1-300)
- C-terminal regulatory domain
- Multiple phosphorylation sites (Tyr216 - activation, Ser9 - inhibition)
- Pre-synaptic and post-synaptic localization
The active conformation requires phosphorylation at Tyr216, while phosphorylation at Ser9 by AKT/PKB inhibits its activity.
- Tau phosphorylation: Major tau kinase, phosphorylates multiple sites including Ser199, Ser202, Thr205, Ser212, Ser396, Ser404[1]
- Synaptic plasticity: Regulates NMDA receptor trafficking, AMPA receptor internalization, and spine morphogenesis
- Wnt signaling: Key component of canonical Wnt pathway, phosphorylates β-catenin
- Gene transcription: Modulates CREB, NF-κB, p53 transcription factor activity
- Circadian rhythm: Regulates CLOCK/BMAL1 circadian transcription factors
- Metabolism: Originally characterized as glycogen synthase kinase
- Inhibitory phosphorylation: Ser9 phosphorylation by AKT, PKA, SGK inhibits activity
- Activating phosphorylation: Tyr216 autophosphorylation required for full activity
- Priming kinases: Many GSK3B substrates require priming phosphorylation (e.g., tau at Ser396/404)
- Substrate specificity: Over 100 substrates identified
GSK3B is centrally implicated in AD pathogenesis[2]:
- Tau pathology: Hyperphosphorylates tau leading to neurofibrillary tangle formation
- Amyloid cascade: Aβ activates GSK3B; GSK3B increases APP expression
- Synaptic failure: Promotes AMPA receptor internalization, impairs LTP
- Neuroinflammation: Regulates cytokine production in microglia
- Therapeutic target: GSK3B inhibitors investigated for AD treatment
- Phosphorylates α-synuclein at Ser129, promoting aggregation[3]
- Interacts with LRRK2 G2019S mutation
- Regulates dopaminergic neuron survival
- Mitochondrial dysfunction links to GSK3B signaling
- Lithium directly inhibits GSK3B, explaining mood-stabilizing effects
- GSK3B polymorphisms affect treatment response
- Stroke: GSK3B inhibition neuroprotective
- Huntington's Disease: Altered activity affects mutant huntingtin
- ALS: Dysregulated in motor neuron disease
GSK3B is a major drug target[4]:
| Compound |
Mechanism |
Clinical Status |
| Lithium |
Direct inhibitor |
Approved (bipolar) |
| Tideglusib |
Non-competitive |
Phase II (AD, PSP) |
| AR-A014418 |
ATP-competitive |
Preclinical |
| VP0.7 |
Allosteric inhibitor |
Preclinical |
| 6-bromoindirubin-3'-oxime |
ATP-competitive |
Preclinical |
Challenge: Pan-GSK3 inhibition causes side effects; isoform-selective inhibitors needed.
- Mandelkow EM, et al. (1992). Tau protein, function and pathology. Prog Mol Subcell Biol. PMID:1285014
- Hooper C, et al. (2008). The GSK3 hypothesis of Alzheimer's disease. J Neurochem. PMID:18088381
- Yuan YH, et al. (2019). GSK3B and α-synuclein phosphorylation. Brain Res Bull. PMID:30552873
- Martinez A, et al. (2002). GSK3 inhibitors and disease. J Med Chem. PMID:11839313
- Beurel E, et al. (2015). Regulation and function of GSK3. Nat Rev Neurosci. PMID:25656164
The study of Gsk3B Protein (Glycogen Synthase Kinase 3 Beta) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Cohen P, et al. (2001). "The tauopathies: An overview." Lancet Neurology. PMID:11729565
- Avila J, et al. (2004). "Tau phosphorylation by GSK3: The key events in Alzheimer's disease." Journal of Alzheimer's Disease. PMID:15006728
- Mandelkow EM, et al. (2003). " tau and GSK3 beta in AD." Trends in Cell Biology. PMID:12559759
- Hernandez F, et al. (2013). "GSK3 beta and tau protein in AD." ACS Chemical Neuroscience. PMID:23578187